Latest
finance.yahoo.com Market update
Beyang Closes Oversubscribed $30 Million Series A Financing
Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co., Ltd. ("Beyang"), an AI-driven innovative drug R&D company dedicated to building a "DreamWorks" for innovative drug discovery, today announced …
Main company
🇭🇰 Hong Kong
Read at finance.yahoo.com